

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116

Serial Number: 09/512,926

Filing Date: February 25, 2000

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALY-COMPROMISED VASCULAR SMOOTH MUSCLE

Page 2
Dkt: 875.039US1Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (Currently amended) A method to normalize the contractile response of an endothelialy-compromised vascular smooth muscle cell in response to a vasoconstrictor agonist in a patient in need of such normalization, comprising administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof.

Claims 2-5 (Cancelled)

Claim 6. (Currently amended) A method of claim 23, wherein the compound administered is 1-p- β -dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.

Claim 7. (Previously presented) A method of claim 23, wherein the patient has diabetes.

Claim 8. (Previously presented) A method of claim 23, wherein the patient has had a surgical procedure.

Claim 9. (Previously presented) A method of claim 23, wherein the patient has hypertension.

Claim 10. (Previously presented) A method of claim 23, wherein the patient has coronary artery disease.

Claim 11. (Previously presented) A method of claim 23, which further comprises administering a pharmaceutically-effective compound selected from the group

Do not
enter
12/11/03

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116

Serial Number: 09/512,926

Filing Date: February 25, 2000


Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALLY-COMPROMISED VASCULAR SMOOTH MUSCLE

Page 3
Dkt 875.039US1

consisting of: an anti-diabetes agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-restenosis agent.

Claims 12-22 (Cancelled)

Claim 23. (Previously presented) A method of claim 1, wherein the CLC3 blocker is a compound of Formula I



wherein

either R⁴ is H or a lower alkyl radical and R⁵ is a lower alkyl radical, or R⁴ and R⁵ are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

R⁶ is H or a lower alkyl radical;

R⁷ is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

R⁸ is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.

Claim 24. (Cancelled)

AMENDMENT & RESPONSE UNDER 37 C.F.R. § 1.116

Serial Number: 09/512,926

Filing Date: February 25, 2000

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALY-COMPROMISED VASCULAR SMOOTH MUSCLEPage 4
Dkt: 875.039US1

Claim 25. (New) A method to normalize the contractile response of an endothelialy-compromised vascular smooth muscle cell in response to a vasoconstrictor agonist in a patient in need of such normalization, comprising administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof, wherein the vasoconstrictor agonist is norepinephrine, KCl or serotonin.